Anti-inflammatory precision from three amino acids
A 3-residue α-MSH fragment with selective anti-inflammatory activity.
Educational content. This page describes KPV for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a licensed provider before starting, stopping, or modifying any therapy.
Enters cells via the PepT1 transporter, accumulates in the nucleus, and competitively blocks the p65/RelA subunit from binding importin-alpha3, preventing NF-kB from reaching DNA and activating pro-inflammatory gene transcription.[3]
Topical KPV achieved 100% corneal re-epithelialization after 60 hours in a rabbit wound model while zero placebo-treated controls showed healing, through a nitric oxide-dependent mechanism.[7]
KPV (Lys-Pro-Val) is a tripeptide corresponding to amino acid residues 11 through 13 at the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Researchers at the University of Munster discovered through systematic amino acid deletion studies that this tiny fragment retains nearly all of alpha-MSH's anti-inflammatory capacity while completely lacking the melanocortin receptor binding domain required for pigmentation effects. It has a molecular weight of approximately 345 daltons.
What makes KPV unusual among anti-inflammatory peptides is its mechanism. It does not bind melanocortin receptors, does not elevate intracellular cAMP, and does not cause pigmentation. Instead, it enters cells through the PepT1 oligopeptide transporter, accumulates in the nucleus, and directly blocks NF-kB from accessing its target genes. This makes it mechanistically distinct from the full alpha-MSH molecule it was derived from.
KPV enters cells via PepT1 (SLC15A1), an oligopeptide transporter expressed broadly in intestinal epithelium and significantly upregulated at sites of intestinal inflammation. Once inside, KPV accumulates in the nucleus where it competitively inhibits the interaction between the NF-kB p65/RelA subunit and importin-alpha3 (specifically arm domains 7 and 8). This blocks the nuclear import step that NF-kB requires to reach DNA and activate pro-inflammatory gene transcription.
KPV does not inhibit the upstream steps of NF-kB activation. IkBa phosphorylation and degradation proceed normally. The peptide specifically intercepts the pathway at the nuclear import checkpoint. Downstream, this suppresses production of TNF-alpha, IL-1beta, IL-6, and IL-8, reduces MMP-9 activity, and attenuates MAP kinase inflammatory signaling.
The PepT1-dependent uptake mechanism provides a form of disease-specific self-targeting in the gut. Because PepT1 expression increases in inflamed tissue, KPV naturally concentrates at the sites where it is most needed. This has driven interest in oral formulations and nanoparticle delivery systems that exploit this targeting for inflammatory bowel conditions.
Anti-inflammatory precision from three amino acids
KPV enters cells via the PepT1 oligopeptide transporter and blocks NF-kB nuclear translocation by competitively inhibiting p65/RelA binding to importin-alpha3. This prevents NF-kB from activating pro-inflammatory genes, suppressing TNF-alpha, IL-1beta, IL-6, IL-8, and MMP-9 production. The mechanism is entirely independent of melanocortin receptor signaling and does not involve cAMP elevation.
Key studies supporting the therapeutic use of this peptide.
KPV was transported into colonocytes via PepT1. Oral KPV reduced incidence and severity of both DSS and TNBS colitis. At nanomolar concentrations, KPV suppressed NF-kB activation and pro-inflammatory cytokine secretion. The anti-inflammatory effect was PepT1-dependent.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. — Gastroenterology, 134(1):166-178 (2008) · PubMed
KPV rescued all animals from death during DSS colitis, including mice completely lacking functional MC1R, confirming the mechanism is independent of melanocortin-1 receptor signaling. Significant reductions in colitis severity, inflammatory infiltrates, and pro-inflammatory cytokines.
Kannengiesser K, Maaser C, Heidemann J, et al. — Inflamm Bowel Dis, 14(3):324-331 (2008) · PubMed
KPV entered cells, accumulated in the nucleus, and competitively inhibited p65/RelA binding to importin-alpha3. It did not block IkBa phosphorylation (the upstream step). Dose-dependent suppression of NF-kB transcriptional activity and IL-8 secretion was confirmed.
Land SC — Int J Physiol Pathophysiol Pharmacol, 4(2):59-73 (2012) · PubMed
Hyaluronic acid-functionalized KPV nanoparticles in chitosan/alginate hydrogel showed significantly stronger mucosal protection and TNF-alpha downregulation versus free KPV at 16 mcg/kg/day. No cytotoxicity observed even after 48 hours of exposure.
Xiao B, Xu Z, Viennois E, et al. — Mol Ther, 25(7):1628-1640 (2017) · PubMed
Typical protocols used in clinical practice. Always consult a licensed provider for personalized dosing.
Subcutaneous Injection
Oral
Topical
Subcutaneous Injection: Standard research protocol. No human clinical trials have established validated dosing.
Oral: Free peptide oral bioavailability is limited. Nanoparticle delivery systems significantly improved efficacy in animal models.
Topical: Corneal wound study used 30 mcL drops of 1 to 10 mg/mL applied 4 times daily.
No formal Phase I human safety trials have been conducted. All dosing information is extrapolated from preclinical models and allometric scaling.
Oral bioavailability of free KPV is limited because the peptide is subject to degradation in the GI tract. Nanoparticle and hydrogel delivery systems showed markedly superior efficacy in animal models, suggesting formulation matters significantly for oral use.
The small molecular size (~345 daltons) and endogenous origin as a fragment of alpha-MSH suggest low immunogenicity risk, but this has not been definitively established in human studies.
KPV does not meet classification criteria for acute toxicity, skin irritation, eye irritation, mutagenicity, carcinogenicity, or reproductive toxicity based on available safety data. No cytotoxicity was observed in multiple cell lines including macrophages, colonic epithelial cells, and bronchial epithelial cells even after 48 hours of exposure.
Unlike broad immunosuppressants, KPV modulates inflammation at the NF-kB nuclear import step without shutting down the entire immune response. No reports of increased infection susceptibility have been published.
The primary safety limitation is the complete absence of formal human clinical trials. All safety and efficacy data comes from cell culture and animal models. The endogenous origin of KPV as a fragment of alpha-MSH provides some reassurance but does not substitute for human trial data.
See how KPV compares to peptides with overlapping benefits.
| Peptide | Primary Use | Administration | Cycle Length | Key Differentiator |
|---|---|---|---|---|
| KPV | Anti-Inflammatory & Wound Healing | Injection, Oral, Topical | 4 to 8 weeks | Smallest known anti-inflammatory peptide that directly blocks NF-kB nuclear import without melanocortin receptor binding, cAMP elevation, or pigmentation effects |
| GHK-Cu | Anti-Aging & Recovery | Topical, Injection | 8–12 weeks | Only peptide demonstrated to modulate ~31% of human genes, epigenetically resetting cellular function toward a younger phenotype |
| Glutathione | Antioxidant & Detoxification | IV, Oral, Sublingual | Ongoing supplementation | The body's own master antioxidant, with clinical data supporting oral bioavailability (challenging earlier assumptions) and dramatic immune cell activation at high doses |
| BPC-157 | Recovery & Healing | Injection, Oral | 4–8 weeks | Uniquely stable in gastric acid; broad multi-system healing with human IBD trial data |
| Thymosin Alpha-1 | Immune Support | Injection | 6–12 months (chronic) / 1–4 weeks (acute) | Only peptide with bidirectional immunomodulation, enhancing suppressed immunity while regulating hyperinflammation, approved in 35+ countries |
Current FDA classification and compounding eligibility.
The FDA placed this substance in Category 2 of the 503A bulk drug substances evaluation, flagging significant safety risks. 503A compounding carries FDA enforcement risk, so most pharmacies decline to prepare it and many physicians hesitate to prescribe it.
In April 2026, HHS Secretary Robert F. Kennedy Jr. announced that nominators withdrew 12 peptides from Category 2 of the FDA's 503A bulk drug substances evaluation, including this one. The FDA referred them to its Pharmacy Compounding Advisory Committee (PCAC) for re-evaluation at meetings beginning July 2026. If PCAC recommends Category 1 status and the FDA agrees, licensed 503A pharmacies could compound it under FDA enforcement discretion again. The outcome is not final.
Listed in Category 2. FDA cited immunogenicity and peptide-related impurity concerns, as well as a lack of human safety data. Not eligible for compounding under the interim policy.
Listed as 'KPV' in 503A Category 2
Last verified April 12, 2026. PepHookup tracks public FDA actions. This is not legal or medical advice.
Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al. “PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.” Gastroenterology, 134(1):166-178 (2008)
Kannengiesser K, Maaser C, Heidemann J, et al. “Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.” Inflamm Bowel Dis, 14(3):324-331 (2008)
Land SC “Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists.” Int J Physiol Pathophysiol Pharmacol, 4(2):59-73 (2012)
Xiao B, Xu Z, Viennois E, et al. “Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis.” Mol Ther, 25(7):1628-1640 (2017)
Viennois E, Ingersoll SA, Ayyadurai S, et al. “Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.” Cell Mol Gastroenterol Hepatol, 2(3):340-357 (2016)
Elliott RJ, Szabo M, Wagner MJ, et al. “alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells.” J Invest Dermatol, 122(4):1010-1019 (2004)
Bonfiglio V, Camillieri G, Avitabile T, et al. “Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide.” Exp Eye Res, 83(6):1366-1372 (2006)
Macaluso A, McCoy D, Ceriani G, et al. “Antiinflammatory influences of alpha-MSH molecules: central neurogenic and peripheral actions.” J Neurosci, 14(4):2377-2382 (1994)
Looking into KPV? Find a provider who knows this peptide and can walk you through your options.
Find a ProviderA tripeptide antioxidant central to cellular redox, detoxification, and immune function.
Produced endogenously and supplemented via IV, injection, or oral routes; clinical evidence remains mixed.
A 28-residue peptide that modulates T-cell maturation and innate immune signaling.
Approved outside the U.S. for chronic hepatitis; domestic compounding remains ineligible after PCAC review.
A 37-residue antimicrobial peptide from the human cathelicidin family.
Broad roles in innate immunity and wound healing; named in the April 2026 HHS Category 2 withdrawal for PCAC re-evaluation.